Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 138Neoplasms 5Neoplasm Metastasis 4Prostate Adenocarcinoma 3Recurrence 2Osteoporosis 2Advanced Prostate Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Sarcopenia 1Radiation Injuries 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1PSA Level Greater Than Two 1Lymphatic Metastasis 1Kidney Diseases 1Hypertension 1Hot Flashes 1Hormone Sensitive Prostate Cancer 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Castrate Sensitive Prostate Cancer 1Anemia 1

Interventions

Goserelin 2radium Ra 223 dichloride 1enzalutamide 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Radiosurgery 1Leuprolide 1Gonadotropin-Releasing Hormone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Prostate Cancer × Goserelin × Genitourinary × Clear all
NCT03936218 2025-04-17

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Eurofarma Laboratorios S.A.

Phase 3 Completed
94 enrolled
Genitourinary

Advanced Prostate Cancer

NCT03971110 2022-12-16

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

AstraZeneca

Phase 4 Terminated
9 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡